http://online.wsj.com/article/PR-CO-20130805-904476.html?mod=googlenews_wsj
Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Aug 5, 2013) - Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has a regenerative medicine device product called ReCell(R) Spray-On Skin(R) (autologous cell suspension), a treatment for severe skin defects, burns, scalds, scars, vitiligo (discoloration of ...
wall street journal avita to dominate
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.02 |
Change
0.050(1.68%) |
Mkt cap ! $205.6M | |||
| Open | High | Low | Value | Volume |
| $2.97 | $3.04 | $2.97 | $665.9K | 221.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $3.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.03 | 5341 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |